表紙:世界のドライアイ症候群治療薬市場(2021年-2025年)
市場調査レポート
商品コード
982423

世界のドライアイ症候群治療薬市場(2021年-2025年)

Global Dry Eye Syndrome Drugs Market 2021-2025

出版日: | 発行: TechNavio (Infiniti Research Ltd.) | ページ情報: 英文 120 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=115.28円
世界のドライアイ症候群治療薬市場(2021年-2025年)
出版日: 2021年01月12日
発行: TechNavio (Infiniti Research Ltd.)
ページ情報: 英文 120 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 目次
概要

世界のドライアイ症候群治療薬の市場規模は、2021年から2025年の間に20億8000万米ドルの成長が見込まれており、予測期間中のCAGRは7%の見込みです。市場は、ライフスタイルの変化や高齢者人口の増加によって推進されています。

当レポートでは、ドライアイ症候群治療薬市場を調査し、市場概要、市場の成長要因および阻害要因の分析、製品別・地域別の市場規模の推移と予測、ベンダー分析、市場機会など、包括的な情報を提供しています。

目次

エグゼクティブサマリー

市場情勢

市場規模

  • 市場の定義
  • 市場セグメント分析
  • 市場規模2020
  • 市場の見通し:2020年から2025年の予測

ファイブフォース分析

製品別の市場セグメンテーション

  • 市場セグメンテーション
  • 製品別の比較
  • OTC薬-市場規模と予測(2020年~2025年)
  • 処方薬-市場規模と予測(2020年~2025年)
  • 製品別の市場機会

顧客情勢

地域別情勢

  • 地域別セグメンテーション
  • 地域別比較
  • 北米-市場規模と予測(2020年~2025年)
  • 欧州-市場規模と予測(2020年~2025年)
  • アジア-市場規模と予測(2020年~2025年)
  • その他の地域-市場規模と予測(2020年~2025年)
  • 主要国
  • 地域の市場機会
  • 市場の推進力
  • 市場の課題
  • 市場動向

ベンダー情勢

  • ベンダー情勢
  • 創造的破壊の状況
  • 競合シナリオ

ベンダー分析

  • 対象ベンダー
  • ベンダーの市場ポジショニング
  • AbbVie Inc.
  • Akorn Inc.
  • Alcon Inc.
  • Bausch Health Companies Inc.
  • Johnson & Johnson
  • Novartis AG
  • Otsuka Holdings Co. Ltd.
  • Prestige Consumer Healthcare Inc.
  • Santen Pharmaceutical Co. Ltd.
  • Sun Pharmaceutical Industries Ltd.

付録

目次
Product Code: IRTNTR46644

Technavio has been monitoring the dry eye syndrome drugs market and it is poised to grow by $ 2.08 bn during 2021-2025 progressing at a CAGR of 7% during the forecast period. Our report on dry eye syndrome drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the changing lifestyle and rising cases of diseases contributing to dry eye syndrome and growing geriatric population. In addition, changing lifestyle and rising cases of diseases contributing to dry eye syndrome is anticipated to boost the growth of the market as well.

The dry eye syndrome drugs market analysis includes product segment and geographical landscapes.

Technavio's dry eye syndrome drugs market is segmented as below:

By Product

  • OTC drugs
  • Prescription drugs

By Geographical Landscapes

  • North America
  • Europe
  • Asia
  • ROW

This study identifies the growing healthcare expenditure as one of the prime reasons driving the dry eye syndrome drugs market growth during the next few years.

"Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on dry eye syndrome drugs market covers the following areas:

  • Dry eye syndrome drugs market sizing
  • Dry eye syndrome drugs market forecast
  • Dry eye syndrome drugs market industry analysis"

Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading dry eye syndrome drugs market vendors that include AbbVie Inc., Akorn Inc., Alcon Inc., Bausch Health Companies Inc., Johnson & Johnson, Novartis AG, Otsuka Holdings Co. Ltd., Prestige Consumer Healthcare Inc., Santen Pharmaceutical Co. Ltd., and Sun Pharmaceutical Industries Ltd.. Also, the dry eye syndrome drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast an accurate market growth.

Table of Contents

Executive Summary

  • Market Overview

Market Landscape

  • Market ecosystem
  • Market characteristics
  • Value chain analysis

Market Sizing

  • Market definition
  • Market segment analysis
  • Market size 2020
  • Market outlook: Forecast for 2020 - 2025

Five Forces Analysis

  • Five forces summary
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

Market Segmentation by Product

  • Market segments
  • Comparison by Product
  • OTC drugs - Market size and forecast 2020-2025
  • Prescription drugs - Market size and forecast 2020-2025
  • Market opportunity by Product

Customer landscape

Geographic Landscape

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2020-2025
  • Europe - Market size and forecast 2020-2025
  • Asia - Market size and forecast 2020-2025
  • ROW - Market size and forecast 2020-2025
  • Key leading countries
  • Market opportunity by geography
  • Market drivers
  • Market challenges
  • Market trends

Vendor Landscape

  • Vendor Landscape
  • Landscape disruption
  • Competitive scenario

Vendor Analysis

  • Vendors covered
  • Market positioning of vendors
  • AbbVie Inc.
  • Akorn Inc.
  • Alcon Inc.
  • Bausch Health Companies Inc.
  • Johnson & Johnson
  • Novartis AG
  • Otsuka Holdings Co. Ltd.
  • Prestige Consumer Healthcare Inc.
  • Santen Pharmaceutical Co. Ltd.
  • Sun Pharmaceutical Industries Ltd.

Appendix

  • Scope of the report
  • Currency conversion rates for US$
  • Research methodology
  • List of abbreviations

Exhibit

  • 1: Key Finding 1
  • 2: Key Finding 2
  • 3: Key Finding 3
  • 4: Key Finding 5
  • 5: Key Finding 6
  • 6: Key Finding 7
  • 7: Key Finding 8
  • 8: Parent market
  • 9: Market characteristics
  • 10: Offerings of vendors included in the market definition
  • 11: Market segments
  • 12: Global - Market size and forecast 2020 - 2025 ($ million)
  • 13: Global market: Year-over-year growth 2020 - 2025 (%)
  • 14: Five forces analysis 2020 & 2025
  • 15: Bargaining power of buyers
  • 16: Bargaining power of suppliers
  • 17: Threat of new entrants
  • 18: Threat of substitutes
  • 19: Threat of rivalry
  • 20: Market condition - Five forces 2020
  • 21: Product - Market share 2020-2025 (%)
  • 22: Comparison by Product
  • 23: OTC drugs - Market size and forecast 2020-2025 ($ million)
  • 24: OTC drugs - Year-over-year growth 2020-2025 (%)
  • 25: Prescription drugs - Market size and forecast 2020-2025 ($ million)
  • 26: Prescription drugs - Year-over-year growth 2020-2025 (%)
  • 27: Market opportunity by Product
  • 28: Customer landscape
  • 29: Market share by geography 2020-2025 (%)
  • 30: Geographic comparison
  • 31: North America - Market size and forecast 2020-2025 ($ million)
  • 32: North America - Year-over-year growth 2020-2025 (%)
  • 33: Europe - Market size and forecast 2020-2025 ($ million)
  • 34: Europe - Year-over-year growth 2020-2025 (%)
  • 35: Asia - Market size and forecast 2020-2025 ($ million)
  • 36: Asia - Year-over-year growth 2020-2025 (%)
  • 37: ROW - Market size and forecast 2020-2025 ($ million)
  • 38: ROW - Year-over-year growth 2020-2025 (%)
  • 39: Key leading countries
  • 40: Market opportunity by geography ($ million)
  • 41: Impact of drivers and challenges
  • 42: Vendor landscape
  • 43: Landscape disruption
  • 44: Industry risks
  • 45: Vendors covered
  • 46: Market positioning of vendors
  • 47: AbbVie Inc. - Overview
  • 48: AbbVie Inc. - Business segments
  • 49: AbbVie Inc. - Key offerings
  • 50: AbbVie Inc. - Key customers
  • 51: AbbVie Inc. - Segment focus
  • 52: Akorn Inc. - Overview
  • 53: Akorn Inc. - Product and service
  • 54: Akorn Inc. - Key offerings
  • 55: Akorn Inc. - Key customers
  • 56: Akorn Inc. - Segment focus
  • 57: Alcon Inc. - Overview
  • 58: Alcon Inc. - Business segments
  • 59: Alcon Inc. - Key offerings
  • 60: Alcon Inc. - Key customers
  • 61: Alcon Inc. - Segment focus
  • 62: Bausch Health Companies Inc. - Overview
  • 63: Bausch Health Companies Inc. - Business segments
  • 64: Bausch Health Companies Inc. - Key offerings
  • 65: Bausch Health Companies Inc. - Key customers
  • 66: Bausch Health Companies Inc. - Segment focus
  • 67: Johnson & Johnson - Overview
  • 68: Johnson & Johnson - Business segments
  • 69: Johnson & Johnson - Key offerings
  • 70: Johnson & Johnson - Key customers
  • 71: Johnson & Johnson - Segment focus
  • 72: Novartis AG - Overview
  • 73: Novartis AG - Business segments
  • 74: Novartis AG - Key offerings
  • 75: Novartis AG - Key customers
  • 76: Novartis AG - Segment focus
  • 77: Otsuka Holdings Co. Ltd. - Overview
  • 78: Otsuka Holdings Co. Ltd. - Business segments
  • 79: Otsuka Holdings Co. Ltd. - Key offerings
  • 80: Otsuka Holdings Co. Ltd. - Key customers
  • 81: Otsuka Holdings Co. Ltd. - Segment focus
  • 82: Prestige Consumer Healthcare Inc. - Overview
  • 83: Prestige Consumer Healthcare Inc. - Business segments
  • 84: Prestige Consumer Healthcare Inc. - Key offerings
  • 85: Prestige Consumer Healthcare Inc. - Key customers
  • 86: Prestige Consumer Healthcare Inc. - Segment focus
  • 87: Santen Pharmaceutical Co. Ltd. - Overview
  • 88: Santen Pharmaceutical Co. Ltd. - Business segments
  • 89: Santen Pharmaceutical Co. Ltd. - Key offerings
  • 90: Santen Pharmaceutical Co. Ltd. - Key customers
  • 91: Santen Pharmaceutical Co. Ltd. - Segment focus
  • 92: Sun Pharmaceutical Industries Ltd. - Overview
  • 93: Sun Pharmaceutical Industries Ltd. - Business segments
  • 94: Sun Pharmaceutical Industries Ltd. - Key offerings
  • 95: Sun Pharmaceutical Industries Ltd. - Key customers
  • 96: Sun Pharmaceutical Industries Ltd. - Segment focus
  • 97: Currency conversion rates for US$
  • 98: Research Methodology
  • 99: Validation techniques employed for market sizing
  • 100: Information sources
  • 101: List of abbreviations